Fig. 4From: AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathwaysThe impact of AC-93253 iodide on cell motility and drug synergism. a Inhibitory effects of AC-93253 iodide on cancer cell invasion as determined by the transwell assay with Matrigel. b Inhibitory effects of AC-93253 iodide on cancer cell migration as determined by the transwell assay without Matrigel. c Synergistic effects of AC-93253 iodide and gefitinib on gefitinib-resistant lung adenocarcinoma cells determined by cell viability assay. The indicated combinations of AC-93253 iodide and gefitinib were used to treat lung adenocarcinoma A549, PC9/gef, and H1975 cells for 72Â h. The CI was calculated using the data and CalcuSyn software. Each experiment was performed independently and was repeated three times. *PÂ <Â 0.05 compared with control (0Â nM; 0.1% DMSO)Back to article page